Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology

Trial Profile

Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 May 2017

At a glance

  • Drugs Azoximer bromide (Primary) ; Bacterial vaccines (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease; Community-acquired pneumonia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top